Image from Google Jackets

Biomarkers for Huntington's Disease : Improving Clinical Outcomes / [E-Book]

Contributor(s):

Series: Contemporary Clinical NeurosciencePublisher: Cham : Springer International Publishing : Imprint: Springer, 2023Edition: 1st ed. 2023Description: XVI, 475 p. 42 illus., 39 illus. in color. online resourceContent type:

text

Media type:

computer

Carrier type:

online resource

ISBN:

9783031328152

Subject(s):

Online resources:

Access resource

Contents:

Molecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers -- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics -- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers -- MRI - non-invasive functional MRI measures -- The evolution of clinical trial methodology.-Digital biomarkers -- The future of telehealth -- Summary and future trends.

Summary: Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents adistinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.

Holdings
Item type	Home library	Class number	URL	Status	Date due	Barcode
Electronic book	Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) Online		Link to resource	Available

Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents adistinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.

There are no comments on this title.

to post a comment.

Storage	Name	Value	Expiration	Description
Cookie	CGISESSID	Session ID	Until logout or end of session	Session cookie
Cookie	KohaOpacLanguage	Language code	3 years	Stores the language the user selected, so the online catalog will appear in that same language the next time it is visited.
Cookie	form_serialized form_serialized_limits	Search terms and limits	End of session or when the advanced search page is accessed again.	jQuery cookie. Stores search terms and limits of the last advanced search. Set when an advanced search is submitted.
Cookie	search_path_code	ads (fewer) or exs (more)	End of session or when the advanced search page is accessed again.	jQuery cookie. Related to serialized_form* cookies. Stores if the advanced search form was used with 'More options' or 'Fewer options'.
Cookie	num_paragraph	Count of search options added	End of session or when the advanced search page is accessed again.	jQuery cookie. Used to store the number of created options when user selects 'More options' in advanced search to increase search boxes.
Cookie	bib_list	List of record IDs (biblionumbers) separated by /	End of session or until the cart is emptied.	Stores cart contents in the online catalog. Set when records are added to the cart for the first time.